Logo image of EDT.CA

SPECTRAL MEDICAL INC (EDT.CA) Stock Fundamental Analysis

TSX:EDT - Toronto Stock Exchange - CA8475771033 - Common Stock - Currency: CAD

0.84  +0.01 (+1.2%)

Fundamental Rating

1

Taking everything into account, EDT scores 1 out of 10 in our fundamental rating. EDT was compared to 24 industry peers in the Biotechnology industry. EDT may be in some trouble as it scores bad on both profitability and health. EDT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EDT had negative earnings in the past year.
EDT had a negative operating cash flow in the past year.
In the past 5 years EDT always reported negative net income.
EDT had a negative operating cash flow in each of the past 5 years.
EDT.CA Yearly Net Income VS EBIT VS OCF VS FCFEDT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -289.53%, EDT is doing worse than 70.83% of the companies in the same industry.
Industry RankSector Rank
ROA -289.53%
ROE N/A
ROIC N/A
ROA(3y)-227.94%
ROA(5y)-174.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EDT.CA Yearly ROA, ROE, ROICEDT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

The Gross Margin of EDT (44.53%) is better than 70.83% of its industry peers.
In the last couple of years the Gross Margin of EDT has declined.
EDT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.21%
GM growth 5Y-10.46%
EDT.CA Yearly Profit, Operating, Gross MarginsEDT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

EDT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EDT has more shares outstanding
The number of shares outstanding for EDT has been increased compared to 5 years ago.
The debt/assets ratio for EDT is higher compared to a year ago.
EDT.CA Yearly Shares OutstandingEDT.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
EDT.CA Yearly Total Debt VS Total AssetsEDT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

2.2 Solvency

Based on the Altman-Z score of -44.99, we must say that EDT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -44.99, EDT is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -44.99
ROIC/WACCN/A
WACC8.3%
EDT.CA Yearly LT Debt VS Equity VS FCFEDT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

2.3 Liquidity

A Current Ratio of 0.16 indicates that EDT may have some problems paying its short term obligations.
EDT has a worse Current ratio (0.16) than 70.83% of its industry peers.
A Quick Ratio of 0.15 indicates that EDT may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.15, EDT is doing worse than 70.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.16
Quick Ratio 0.15
EDT.CA Yearly Current Assets VS Current LiabilitesEDT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for EDT have decreased strongly by -42.70% in the last year.
Looking at the last year, EDT shows a decrease in Revenue. The Revenue has decreased by -4.31% in the last year.
EDT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -16.08% yearly.
EPS 1Y (TTM)-42.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.2%
Revenue 1Y (TTM)-4.31%
Revenue growth 3Y-8.7%
Revenue growth 5Y-16.08%
Sales Q2Q%-18.61%

3.2 Future

EDT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.21% yearly.
The Revenue is expected to grow by 18.82% on average over the next years. This is quite good.
EPS Next Y-23.87%
EPS Next 2Y21.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year23.53%
Revenue Next 2Y18.82%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EDT.CA Yearly Revenue VS EstimatesEDT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M
EDT.CA Yearly EPS VS EstimatesEDT.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 -0.02 -0.04 -0.06 -0.08

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EDT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EDT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EDT.CA Price Earnings VS Forward Price EarningsEDT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EDT.CA Per share dataEDT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06 -0.08

4.3 Compensation for Growth

EDT's earnings are expected to grow with 21.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.21%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EDT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPECTRAL MEDICAL INC

TSX:EDT (5/26/2025, 7:00:00 PM)

0.84

+0.01 (+1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-07 2025-08-07
Inst Owners0.04%
Inst Owner ChangeN/A
Ins Owners1.4%
Ins Owner ChangeN/A
Market Cap239.50M
Analysts84
Price Target2.35 (179.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15%
PT rev (3m)15%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 104.77
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.01
BVpS-0.1
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -289.53%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.53%
FCFM N/A
ROA(3y)-227.94%
ROA(5y)-174.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.21%
GM growth 5Y-10.46%
F-Score5
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.76%
Cap/Sales 1.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.16
Quick Ratio 0.15
Altman-Z -44.99
F-Score5
WACC8.3%
ROIC/WACCN/A
Cap/Depr(3y)35.44%
Cap/Depr(5y)73.91%
Cap/Sales(3y)4.85%
Cap/Sales(5y)10.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.2%
EPS Next Y-23.87%
EPS Next 2Y21.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.31%
Revenue growth 3Y-8.7%
Revenue growth 5Y-16.08%
Sales Q2Q%-18.61%
Revenue Next Year23.53%
Revenue Next 2Y18.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.75%
OCF growth 3YN/A
OCF growth 5YN/A